Skip to main content

Nyxoah S.A. (NYXH) Stock Forecast

Data as of Aug 6, 2026

Healthcare · Current price $1.32 (-6.03%)

Consensus Target
$6.00
Upside
+207.9%
Analysts
6
Rating
Buy(2.33)

Price Target Range

Low $5.00Consensus $6.00High $7.00
▲ Current $1.32

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold2
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

NYXH vs Sector & Market

MetricNYXHHealthcare AvgLarge Cap Avg
Analyst Rating2.332.252.42
Analyst Count6818
Target Upside+207.9%+16315.9%+17.2%
P/E Ratio-1.143.2135.79

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$8M$9M$10M2
2026-12-31$9M$10M$11M3
2027-03-31$12M$13M$14M3
2027-06-30$15M$17M$18M2
2027-09-30$18M$19M$21M2
2027-12-31$21M$23M$24M3
2028-12-31$109M$120M$129M3
2029-12-31$227M$251M$269M2
2030-12-31$327M$362M$387M1

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-0.51$-0.47$-0.421
2026-12-31$-0.43$-0.39$-0.352
2027-03-31$-0.39$-0.36$-0.322
2027-06-30$-0.39$-0.35$-0.321
2027-09-30$-0.34$-0.31$-0.281
2027-12-31$-0.32$-0.29$-0.262
2028-12-31$-0.94$-0.86$-0.751
2029-12-31$0.18$0.21$0.231
2030-12-31$0.61$0.70$0.761

Frequently Asked Questions

What is the analyst consensus for NYXH?

The consensus among 6 analysts covering Nyxoah S.A. (NYXH) is Buy with an average price target of $6.00.

What is the highest price target for NYXH?

The highest analyst price target for NYXH is $7.00.

What is the lowest price target for NYXH?

The lowest analyst price target for NYXH is $5.00.

How many analysts cover NYXH?

6 analysts have issued ratings for Nyxoah S.A. in the past 12 months.

Is NYXH a buy or sell right now?

Based on 6 analyst ratings, NYXH has a consensus rating of Buy (2.33/5) with a +207.9% upside to the consensus target of $6.00.

What are the earnings estimates for NYXH?

Analysts estimate NYXH will report EPS of $-0.47 for the period ending 2026-09-30, with revenue estimated at $9M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.